AHA/ACC guideline adds Camzyos as a treatment for oHCM

On Wednesday, the American Heart Association (AHA)/American College of Cardiology (ACC) Joint Committee on Clinical Practice Guidelines issued a  new clinical guideline for the evaluation and management of people with hypertrophic cardiomyopathy (HCM).

The guideline now recommends US pharma major Bristol Myers Squibb’s (NYSE: BMY) Camzyos (mavacamten), the first and only Food and Drug Administration (FDA)-approved cardiac myosin inhibitor, as a Class 1 Level B-R therapy for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III obstructive HCM (oHCM).

This update represents a significant evolution in symptomatic oHCM care and provides cardiologists with evidence-based recommendations in prescribing Camzyos to patients with symptomatic oHCM who do not derive adequate symptomatic relief from first-line drug therapy.